Companies that use Medidata Rave

Source: Analysis of 100 job postings that mention Medidata Rave

My analysis shows that Directors of Data Management represent 39% of roles mentioning Medidata Rave, making them the clear buying authority. These leaders sit within Clinical Development, Biometrics, and R&D organizations at biotech and pharmaceutical companies. They're hiring to support expanding clinical trial portfolios, particularly Phase 2 and Phase 3 oncology programs. Their strategic priorities center on vendor oversight, regulatory compliance, and building scalable data infrastructure to accelerate timelines and ensure submission-ready data.

The day-to-day users are Clinical Data Managers, EDC Programmers, and Clinical Database Designers who represent the specialized practitioner layer. These professionals design eCRFs, build edit checks and validation rules, configure study databases, manage user access, perform data cleaning and query resolution, and ensure integration with external systems like CTMS and safety databases. They work extensively with CDISC standards and coordinate closely with Biostatistics, Clinical Operations, and Medical Affairs teams throughout the trial lifecycle.

The recurring pain points reveal companies seeking to transform antiquated processes into modern, efficient systems. I found phrases like "accelerate timelines" and "timely delivery of high-quality, submission-ready data" appearing repeatedly. Organizations want to "drive continuous improvement" and implement "risk-based data management strategies." Many postings emphasize the need to "oversee CROs and vendors" effectively while maintaining "data integrity, accuracy, and completeness." The emphasis on regulatory inspections and 21 CFR Part 11 compliance signals that audit-readiness remains a critical concern driving technology investments.

Source: Analysis of tech stacks from 364 companies that use Medidata Rave

I noticed something striking about companies using Medidata Rave: they're almost exclusively life sciences organizations running clinical trials. The combination of tools here screams pharmaceutical, biotech, and contract research organizations managing the complex regulatory and operational demands of drug development.

The pairing with Veeva Vault makes perfect sense because both tools address different aspects of clinical trial management. While Medidata Rave handles electronic data capture during trials, Veeva Vault manages regulatory documents, study materials, and submission packages. Together they create an end-to-end system for bringing drugs to market. The presence of eClinical Solutions and Benchling reinforces this pattern. eClinical provides additional clinical trial management capabilities, while Benchling handles the earlier R&D phase, particularly around biologics and cell therapies. Companies using all these tools are managing the entire drug development lifecycle from discovery through regulatory approval.

The full stack reveals these are process-driven, compliance-heavy organizations. They're definitely not product-led growth companies. Instead, they operate through highly structured procurement processes with long sales cycles and serious validation requirements. Many are likely mid-stage or mature biotechs with active clinical programs, or established pharma companies. The presence of Mastercontrol and Agiloft, both focused on quality management and contract lifecycle management, confirms they're dealing with FDA regulations, vendor agreements, and audit trails at every turn.

Source: Analysis of Linkedin bios of 364 companies that use Medidata Rave

I noticed that Medidata Rave users are overwhelmingly biopharmaceutical and biotechnology companies developing novel therapeutics, particularly in oncology and rare diseases. These aren't traditional pharmaceutical manufacturers. They're R&D-focused organizations creating first-in-class or best-in-class treatments using cutting-edge approaches like CAR-T cell therapy, antibody-drug conjugates, bispecific antibodies, and immunotherapies. Many are pioneering entirely new treatment modalities rather than developing incremental improvements to existing drugs.

These companies span a wide maturity range, but most are clinical-stage or recently commercial. I see many in Phase 1, Phase 2, or Phase 3 trials, with employee counts typically between 50-500 people. Funding stages cluster around Series B, Series C, and post-IPO equity rounds. Several are backed by top-tier venture capital or have strategic pharmaceutical partnerships. The mix includes both well-funded startups with $100M+ raises and established public companies, but even the mature players describe themselves as innovation-driven rather than purely commercial entities.